Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients
A phase 1/2 trial of Sotorasib in non-small-cell lung cancer and small-cell lung cancer, run by Verastem, Inc., active and no longer recruiting.
Overview
Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients is a phase 1/2 interventional study registered as NCT05074810 by Verastem, Inc., with 153 participants planned, started 2022-04-12 and due to reach its primary completion in 2026-06. Interventions recorded: avutometinib and sotorasib, avutometinib and sotorasib and defactinib. Conditions listed: Non Small Cell Lung Cancer, KRAS Activating Mutation. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
Shares Verastem Oncology, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants Wi
Shares Sotorasib, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Shares Verastem Oncology, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA 2-part Phase 1/2 Open-label Trial on ODM-212
Shares Sotorasib, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialCodeBreaK 200
Shares Sotorasib, Non-small-cell lung cancer.
- TrialKrascendo 1
Shares Sotorasib, Non-small-cell lung cancer.
- PersonKevan M. Shokat
Shares Sotorasib, Non-small-cell lung cancer.
- TreatmentVS-7375